iOmx is generating a pipeline of proprietary drug candidates against its novel immune-oncology programs. Leveraging its systematic approach to identify novel checkpoint modulators directly on tumor samples using the iOTargTM platform, iOmx is unveiling organ-specific tumor evasion strategies to develop the next-generation of targeted cancer immunotherapies which have monotherapy potential. The company’s lead candidate OMX-0407, a novel SIK inhibitor, is currently being investigated in a first-in-human clinical trial.
OMX-0407 – a novel SIK inhibitor:
With a novel mode of action iOmx’s lead candidate has the potential to treat various solid tumors that are resistant to conventional immune checkpoint inhibitors. OMX-0407 is an oral spectrum-selective salt-inducible kinase (SIK) inhibitor. SIK3 is a member of the SIK family that controls the NF-B driven gene landscape through phosphorylation of class IIa histone deacetylases (HDACs) and CREB-regulated transcriptional coactivators (CRTCs), allowing the tumor to evade death receptor-mediated killing. In preclinical studies, OMX-0407 enhances apoptosis by death receptor ligands such as tumor necrosis factor (TNF) and TNF related apoptosis-inducing ligand (TRAIL).
Clinical development of OMX-0407
OMX-0407 is currently being investigated in a Phase I clinical study (NCT05826600) to assess its safety, tolerability, and pharmacodynamic efficacy. This first-in-human trial is evaluating OMX-0407 as monotherapy in patients with previously treated unresectable solid tumors and follows a 3+3 dose escalation scheme to determine the maximum tolerated dose (MTD).
To learn more about potential partnering opportunities, please contact us at: firstname.lastname@example.org